Heterogeneity in the effects of reward- and deposit-based financial incentives on smoking cessation

American Journal of Respiratory and Critical Care Medicine

Volumn 194, Issue 8, 2016, Pages 981-988

  Halpern, Scott D ^a,b   French, Benjamin ^b   Small, Dylan S ^b,c   Saulsgiver, Kathryn ^b   Harhay, Michael O ^b   Audrain McGovern, Janet ^b   Loewenstein, George ^b,d   Asch, David A ^a,b,c,e   Volpp, Kevin G ^a,b,c,e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d CARNEGIE MELLON UNIVERSITY   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Behavior change; Financial incentives; Heterogeneity of treatment effect; Smoking cessation

Indexed keywords

ADULT; ARTICLE; BLACK PERSON; CAUCASIAN; DELAY DISCOUNTING; FEMALE; HIGHEST INCOME GROUP; HOUSEHOLD INCOME; HUMAN; IMPULSIVENESS; INCOME; MALE; NORMAL HUMAN; PHENOTYPE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGRAM EFFECTIVENESS; PSYCHOLOGICAL ASPECT; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REIMBURSEMENT; REWARD; SECONDARY ANALYSIS; SMOKING CESSATION; TOBACCO DEPENDENCE; AGE; CONTROLLED STUDY; EDUCATIONAL STATUS; MARRIAGE; MIDDLE AGED; MOTIVATION; PREVENTION AND CONTROL; PROCEDURES; PROGRAM EVALUATION; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; SMOKING;

ADULT; AGE FACTORS; EDUCATIONAL STATUS; FEMALE; HUMANS; INCOME; MALE; MARITAL STATUS; MIDDLE AGED; MOTIVATION; PROGRAM EVALUATION; REWARD; SMOKING; SMOKING CESSATION;

EID: 84992365525     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201601-0108OC     Document Type: Article

References (39)

1. Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, Murray CJ, Ezzati M. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med 2009;6:e1000058.
2. Rostron BL, Chang CM, Pechacek TF. Estimation of cigarette smokingattributable morbidity in the United States. JAMA Intern Med 2014; 174:1922-1928.
3. Halpern SD, French B, Small DS, Saulsgiver K, Harhay MO, Audrain-McGovern J, Loewenstein G, Brennan TA, Asch DA, Volpp KG. Randomized trial of four financial-incentive programs for smoking cessation. N Engl J Med 2015; 372:2108-2117.
4. Volpp KG, Troxel AB, Pauly MV, Glick HA, Puig A, Asch DA, Galvin R, Zhu J, Wan F, DeGuzman J, et al. A randomized, controlled trial of financial incentives for smoking cessation. N Engl J Med 2009;360: 699-709.
5. Cahill K, Hartmann-Boyce J, Perera R. Incentives for smoking cessation. Cochrane Database Syst Rev 2015;5:CD004307.
6. Volpp KG, Das A. Comparative effectiveness: thinking beyond medication A versus medication B. N Engl J Med 2009;361:331-333.
7. Volpp KG, Asch DA, Galvin R, Loewenstein G. Redesigning employee health incentives: lessons from behavioral economics. N Engl J Med 2011;365:388-390.
8. Health Care Survey Finds Spending on Corporate Wellness Incentives to Increase 15 Percent in 2014 [accessed 2015 July 3]. Available from: http://www.fidelity.com/inside-fidelity/employer-services/health-caresurvey- finds-spending
9. Haff N, Patel MS, Lim R, Zhu J, Troxel AB, Asch DA, Volpp KG. The role of behavioral economic incentive design and demographic characteristics in financial incentive-based approaches to changing health behaviors: a meta-analysis. Am J Health Promot 2015;29: 314-323.
10. French B, Small DS, Novak J, Saulsgiver KA, Harhay MO, Asch DA, Volpp KG, Halpern SD. Preference-adaptive randomization in comparative effectiveness studies. Trials 2015;16:99.
11. Halpern SD, Asch DA, Volpp KG. Commitment contracts as a way to health. BMJ 2012;344:e522.
12. Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res 2003;5:13-25.
13. Benowitz NL, Ahijevch K, Hall S, LeHoueze J, Hanson A, Lichtenstein E, Henningfield J, Tsoh J, Hurt RD; SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine Tob Res 2002;4:149-159.
14. Jacob P III, Hatsukami D, Severson H, Hall S, Yu L, Benowitz NL. Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev 2002;11:1668-1673.
15. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2013.
16. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr 1974;19:716-723.
17. Kahan BC, Morris TP. Improper analysis of trials randomised using stratified blocks or minimisation. Stat Med 2012;31:328-340.
18. Piper ME, Cook JW, Schlam TR, Jorenby DE, Smith SS, Bolt DM, Loh WY. Gender, race, and education differences in abstinence rates among participants in two randomized smoking cessation trials. Nicotine Tob Res 2010;12:647-657.
19. Prochaska JO, DiClemente CC, Norcross JC. In search of how people change. Applications to addictive behaviors. Am Psychol 1992;47: 1102-1114.
20. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991;86: 1119-1127.
21. MacPhillamy DJ, Lewinsohn PM. Manual for the pleasant events schedule. Eugene, OR: University of Oregon; 1976.
22. Audrain-McGovern J, Rodriguez D, Epstein LH, Rodgers K, Cuevas J, Wileyto EP. Young adult smoking: what factors differentiate exsmokers, smoking cessation treatment seekers and nontreatment seekers? Addict Behav 2009;34:1036-1041.
23. Kirby K. Bidding on the future: evidence against normative discounting of delayed rewards. J Exp Psychol Gen 1997;126:54-70.
24. Mitchell SH. Measures of impulsivity in cigarette smokers and nonsmokers. Psychopharmacology (Berl) 1999;146:455-464.
25. Reynolds B, Richards JB, Horn K, Karraker K. Delay discounting and probability discounting as related to cigarette smoking status in adults. Behav Processes 2004;65:35-42.
26. Dohmen T, Falk A, Huffman D, Sunde U, Schupp J, Wagner GG. Individual risk attitudes: measurement, determinants, and behavioral consequences. J Eur Econ Assoc 2011;9:522-550.
27. Zona F. Corporate investing as a response to economic downturn: prospect theory, the behavioural agency model and the role of financial slack. Br J Manage 2012;23:S42-S57.
28. Sheffer CE, Christensen DR, Landes R, Carter LP, Jackson L, Bickel WK. Delay discounting rates: a strong prognostic indicator of smoking relapse. Addict Behav 2014;39:1682-1689.
29. Sheffer C, Mackillop J, McGeary J, Landes R, Carter L, Yi R, Jones B, Christensen D, Stitzer M, Jackson L, et al. Delay discounting, locus of control, and cognitive impulsiveness independently predict tobacco dependence treatment outcomes in a highly dependent, lower socioeconomic group of smokers. Am J Addict 2012;21: 221-232.
30. Senecal N, Wang T, Thompson E, Kable JW. Normative arguments from experts and peers reduce delay discounting. Judgm Decis Mak 2012;7:568-589.
31. Hershfield HE, Goldstein DG, Sharpe WF, Fox J, Yeykelis L, Carstensen LL, Bailenson JN. Increasing saving behavior through ageprogressed renderings of the future self. J Mark Res 2011;48: S23-S37.
32. Peters J, Büchel C. Episodic future thinking reduces reward delay discounting through an enhancement of prefrontal-mediotemporal interactions. Neuron 2010;66:138-148.
33. Liu L, Feng T, Chen J, Li H. The value of emotion: how does episodic prospection modulate delay discounting? PLoS One 2013;8:e81717.
34. Newhouse JP, McClellan M. Econometrics in outcomes research: the use of instrumental variables. Annu Rev Public Health 1998;19: 17-34.
35. Angrist JD, Imbens GW, Rubin DB. Identification of causal effects using instrumental variables. J Am Stat Assoc 1996;91:444-455.
36. Sussman JB, Hayward RA. An IV for the RCT: using instrumental variables to adjust for treatment contamination in randomised controlled trials. BMJ 2010;340:c2073.
37. Cheng J, Small D. Bounds on causal effects in three-arm trials with noncompliance. J R Stat Soc B 2006;68:815-836.
38. Cheng J, Small D, Tan Z, Ten Have T. Efficient nonparametric estimation of causal effects in randomized trials with noncompliance. Biometrika 2009;96:19-36.
39. Towers Watson/National Business Group on Health. Employer survey on purchasing value in health care [accessed 2015 Aug 21]. Available from: http://www.towerswatson.com/en-US/Insights/IC-Types/Survey-Research-Results/2014/05/full-report-towers-watsonnbgh- 2013-2014-employer-survey-on-purchasing-value-inhealth- Care